Search
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalSimilar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer
AP5346
go.drugbank.com/drugs/DB04992InvestigationalAP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. ...
AX200
go.drugbank.com/drugs/DB05093InvestigationalAX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased af...
C31G
go.drugbank.com/drugs/DB05398InvestigationalC31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical t...
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measure...
Aranidipine
go.drugbank.com/drugs/DB09229ExperimentalAranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity. It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-n...
GLB-001
go.drugbank.com/drugs/DB32795InvestigationalGLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).
Tiapride
go.drugbank.com/drugs/DB13025InvestigationalTiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
Elesclomol
go.drugbank.com/drugs/DB05719InvestigationalElesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad r...